Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, School of Medicine, U. C. Davis , Sacramento, CA, USA.
Department of Emergency Medicine, School of Medicine, U. C. Davis , Sacramento, CA, USA.
Expert Opin Pharmacother. 2020 Nov;21(16):1991-2010. doi: 10.1080/14656566.2020.1795131. Epub 2020 Jul 20.
Asthma is a heterogeneous syndrome with variable phenotypes. Reversible airway obstruction and airway hyper-responsiveness often with an atopic or eosinophilic component is common in the elderly asthmatic. Asthma chronic obstructive pulmonary disease overlap syndrome (ACOS), a combination of atopy-mediated airway hyper-responsiveness and a history of smoking or other environmental noxious exposures, can lead to some fixed airway obstruction and is also common in elderly patients. Little specific data exist for the treating the elderly asthmatic, thus requiring the clinician to extrapolate from general adult data and asthma treatment guidelines.
A stepwise approach to pharmacotherapy of the elderly patient with asthma and ACOS is offered and the literature supporting the use of each class of drugs reviewed.
Inhaled, long-acting bronchodilators in combination with inhaled corticosteroids represent the backbone of treatment for the elderly patient with asthma or ACOS . Beyond these medications used as direct bronchodilators and topical anti-inflammatory agents, a stepwise approach to escalation of therapy includes multiple options such as oral leukotriene receptor antagonist or 5-lipoxygense inhibitor therapy, oral phosphodiesterase inhibitors, systemic corticosteroids, oral macrolide antibiotics and if evidence of eosinophilic/atopic component disease exists then modifying monoclonal antibody therapies.
哮喘是一种具有不同表型的异质性综合征。在老年哮喘患者中,常伴有可逆性气道阻塞和气道高反应性,且常伴有特应性或嗜酸性粒细胞成分。哮喘-慢性阻塞性肺疾病重叠综合征(ACOS)是特应性介导的气道高反应性和吸烟或其他环境有害暴露史的结合,可导致部分固定气道阻塞,也常见于老年患者。针对老年哮喘患者的治疗数据较少,因此需要临床医生从一般成人数据和哮喘治疗指南中推断。
为老年哮喘和 ACOS 患者提供了一种逐步的药物治疗方法,并对支持每种药物类别的使用的文献进行了回顾。
吸入长效支气管扩张剂联合吸入皮质激素是治疗老年哮喘或 ACOS 患者的基础。除了这些作为直接支气管扩张剂和局部抗炎药物使用的药物外,治疗方案的逐步升级还包括多种选择,如口服白三烯受体拮抗剂或 5-脂氧合酶抑制剂治疗、口服磷酸二酯酶抑制剂、全身皮质激素、口服大环内酯类抗生素,如果存在嗜酸性粒细胞/特应性成分疾病的证据,则采用修饰性单克隆抗体治疗。